EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts

Jesse Demuytere iD, Charlotte Carlier, Leen Van de Sande, Anne Hoorens iD, Kaat De Clercq, Silvia Giordano, Lavinia Morosi, Cristina Matteo, Massimo Zucchetti, Enrico Davoli, Jo Van Dorpe iD, Chris Vervaet und 1 weitere

International Journal of Nanomedicine · 2024

DOI: 10.2147/ijn.s424045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2024. Verfasst von Jesse Demuytere und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of GI Surgery, Ghent University Hospital, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epithelial ovarian cancer is associated with high mortality due to diagnosis at later stages associated with peritoneal involvement. Several trials have evaluated the effect of intraperitoneal treatment. In this preclinical study, we report the efficacy, pharmacokinetics and pharmacodynamics of intraperitoneal treatment with two approved nanomolecular formulations of paclitaxel (nab-PTX and mic-PTX) in a murine ovarian cancer xenograft model.

Methods

IC50 was determined in vitro on three ovarian cancer cell lines (OVCAR-3, SK-OV-3 and SK-OV-3-Luc IP1). EOC xenografts were achieved using a modified subperitoneal implantation technique. Drug treatment was initiated 2 weeks after engraftment, and tumor volume and survival were assessed. Pharmacokinetics and drug distribution effects were assessed using UHPLC-MS/MS and MALDI imaging mass spectrometry, respectively. Pharmacodynamic effects were analyzed using immunohistochemistry and transmission electron microscopy using standard protocols.

Results

We demonstrated sub-micromolar IC50 concentrations for both formulations on three EOC cancer cell lines in vitro. Furthermore, IP administration of nab-PTX or mic-PTX lead to more than 2-fold longer survival compared to a control treatment of IP saline administration (30 days in controls, 66 days in nab-PTX treated animals, and 76 days in mic-PTX animals, respectively). We observed higher tissue uptake of drug following nab-PTX administration when compared to mic-PTX, with highest uptake after 4 hours post-treatment, and confirmed this lower uptake of mic-PTX using HPLC on digested tumor samples. Furthermore, apoptosis was not increased in tumor implants up to 24h post-treatment.

Conclusion

Intraperitoneal administration of both nab-PTX and mic-PTX results in a significant anticancer efficacy and survival benefit in a mouse OC xenograft model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHumansAnimalsFemaleMicePaclitaxelHeterograftsApoptosisTandem Mass SpectrometryCell Line, TumorDisease Models, Animal

Stichwörter der Autor:innen

nanomedicineovarianpaclitaxelperitoneal

Substanzen

Paclitaxel

Autor:innen und Institutionen

  • Department of GI Surgery, Ghent University Hospital, and Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
  • Department of Pathology, Ghent University Hospital, Ghent, Belgium.
  • Laboratory of Pharmaceutical Technology, Ghent University, Ghent, Belgium.
  • Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milano, Italy.

ORCID-Profile: Jesse Demuytere, Anne Hoorens, Jo Van Dorpe

Zitieren

APA

Demuytere, J., Carlier, C., Van de Sande, L., Hoorens, A., De Clercq, K., Giordano, S., Morosi, L., Matteo, C., Zucchetti, M., Davoli, E., Van Dorpe, J., Vervaet, C., & Ceelen, W. (2024). Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s424045

Vancouver

Demuytere J, Carlier C, Van de Sande L, Hoorens A, De Clercq K, Giordano S, et al. Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts. International Journal of Nanomedicine. 2024. doi:10.2147/ijn.s424045

BibTeX
@article{Demuytere2024,
  author = {Demuytere, Jesse and Carlier, Charlotte and Van de Sande, Leen and Hoorens, Anne and De Clercq, Kaat and Giordano, Silvia and Morosi, Lavinia and Matteo, Cristina and Zucchetti, Massimo and Davoli, Enrico and Van Dorpe, Jo and Vervaet, Chris and Ceelen, Wim},
  title = {Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts},
  journal = {International Journal of Nanomedicine},
  year = {2024},
  doi = {10.2147/ijn.s424045}
}
Kostenlos starten →